Educating Breast Cancer Patients Reduces Radiation Dermatitis Severity

Article

Patient education can improve adherence to skin-care plans and reduce radiation dermatitis among patients undergoing radiotherapy for breast cancer.

Patient education can improve adherence to skin-care plans and reduce radiation dermatitis (RD) among patients undergoing radiotherapy for breast cancer, researchers reported in a poster session at the Oncology Nursing Society (ONS) 42nd Annual Congress, held May 4–7 in Denver.

“Our data suggest that using a highly structured evidence-based multimedia education program with planned reinforcements to teach breast cancer patients about skin care during radiation therapy has a demonstrable positive effect on levels of adherence … and a significant decrease in the severity of RD,” reported lead study author Lena Andriths, BSN, RN, OCN, and colleagues at the Barbara Ann Karmanos Cancer Institute at Wayne State University in Detroit.

More than 95% of patients undergoing cancer radiotherapy experience RD, impairing function and quality of life. The researchers sought to assess the effects on skin-care adherence (use of Aquaphor and wipes twice daily) among women undergoing breast cancer radiotherapy, using an education intervention based on ONS Putting Evidence Into Practice and World Health Organization adherence models.

Oncology nurses were trained to provide verbal instructions.

“Initially, patients received multimethod (verbal, written, video) pretreatment instructions about skin care,” the authors explained. “Planned reinforcement occurred at treatment weeks 1 and 3 using the patient’s preferred method (verbal, written, or video).”

“There was a sharp increase in adherence to the recommended skin-care protocol from week 1 to week 2, moving from 29% to 95%,” they reported.

A second, modest increase occurred by week 4, when adherence reached 100%. However, time to onset of skin toxicity was similar among the intervention group compared to a previous cohort (median time to onset, 17 vs 17.5 days).

The frequency of severe (grade 3/4) RD was significantly lower in the intervention group (chi square = 4.61; P = .03).

“An important finding from the study was that the severity of RD was significantly less among patients using the new protocol compared to those who did not,” the authors reported. “These findings differ substantially from our earlier work with head and neck patients where there was no difference in the severity of RD.”

Scheduled reinforcements in the intervention appeared to have a substantial impact on adherence, they noted.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.